Clinic for Infectious and Tropical Diseases, University Clinical Center of Serbia, Belgrade, Serbia.
Clinic for Cardiology, University Clinical Center of Serbia, Belgrade, Serbia.
J Infect Dev Ctries. 2024 May 30;18(5):694-700. doi: 10.3855/jidc.18802.
The coronavirus disease 2019 (COVID-19) pandemic started in March 2020. Since then, there has been an urgent need for effective therapeutic methods to manage the disease. We aimed to assess the effectiveness of molnupiravir in reducing the need for hospitalization in at-risk, non-hospitalized COVID-19 patients.
This was a single-center, non-randomized, observational retrospective study of non-hospitalized patients with confirmed COVID-19, treated at the Clinic for Infectious and Tropical Diseases, University Clinical Center in Belgrade, Serbia.
The study was conducted between 15 December 2021 and 15 February 2022 and included 320 patients. Of these, 165 (51.6%) received treatment with molnupiravir. The study and control groups were similar in gender and age distribution. The study group had a higher proportion of vaccination (75.2% vs. 51%, p < 0.001). There was no statistically significant difference in presence of comorbidity within the groups. Majority of the patients who received molnupiravir did not require hospitalization; and this was statistically significant in comparison to control group (92.7 vs. 24.5%, p < 0.001). Oxygen supplementation was less frequently required in the study group compared to the control group (0.6% vs. 31%, p < 0.001). During the follow-up period of 12.12 ± 3.5 days, significantly less patients from the study group were admitted to the intensive care unit (p < 0.001). Molnupiravir significantly reduced the risk of hospitalization by 97.9% (HR 0.021; 95% CI 0.005-0.089; p < 0.001).
Molnupiravir is an effective therapy in preventing the development of severe forms of COVID-19 and hospitalization.
2019 年冠状病毒病（COVID-19）大流行始于 2020 年 3 月。自那时以来，迫切需要有效的治疗方法来控制该疾病。我们旨在评估莫努匹韦在减少高危、非住院 COVID-19 患者住院需求方面的有效性。
这是一项在塞尔维亚贝尔格莱德大学临床中心传染病和热带病诊所接受治疗的确诊 COVID-19 非住院患者的单中心、非随机、观察性回顾性研究。
该研究于 2021 年 12 月 15 日至 2022 年 2 月 15 日进行，共纳入 320 例患者。其中，165 例（51.6%）接受莫努匹韦治疗。研究组和对照组在性别和年龄分布上相似。研究组的疫苗接种比例较高（75.2%比 51%，p<0.001）。组内合并症的存在无统计学差异。接受莫努匹韦治疗的大多数患者无需住院；与对照组相比，这具有统计学意义（92.7%比 24.5%，p<0.001）。与对照组相比，研究组需要氧疗的患者较少（0.6%比 31%，p<0.001）。在 12.12±3.5 天的随访期间，研究组患者入住重症监护病房的人数明显较少（p<0.001）。莫努匹韦可显著降低 97.9%的住院风险（HR 0.021；95%CI 0.005-0.089；p<0.001）。
莫努匹韦是预防 COVID-19 严重形式和住院的有效治疗方法。
